Which antihypertensive medications are safe to use in patients with severe aortic stenosis?

Antihypertensive Medications Safe in Severe Aortic Stenosis

In patients with severe aortic stenosis and hypertension, ACE inhibitors or ARBs (renin-angiotensin system blockers) are the preferred first-line agents, started at low doses and gradually titrated upward with close monitoring. 1, 2

Primary Recommendation: RAS Blockade

The 2017 ACC/AHA guidelines provide a Class I, Level B-NR recommendation that hypertension in patients with asymptomatic aortic stenosis should be treated with pharmacotherapy, starting at low doses and gradually titrating upward as needed 1, 2. While no specific drug class receives exclusive endorsement, RAS blockade (ACE inhibitors or ARBs) may be advantageous due to potentially beneficial effects on LV fibrosis, control of hypertension, reduction of dyspnea, and improved effort tolerance 1, 2, 1.

Recent evidence strongly supports this approach:

• A 2023 study demonstrated that ACE inhibitors/ARBs reduced 2-year cardiovascular mortality by 56% (HR 0.44,95% CI: 0.23-0.81) in hypertensive patients with severe AS undergoing TAVI 3
• A 2020 meta-analysis of 26,500 patients found that RAS inhibitors were associated with reduced mortality risk (Pooled HR 0.58,95% CI 0.43-0.80) in moderate-to-severe AS 4
• The 2020 ACC/AHA guidelines give a Class 2b recommendation for RAS blockers post-TAVI to reduce long-term all-cause mortality 5

Alternative Agents by Clinical Context

Beta-Blockers

Beta-blockers are appropriate for patients with aortic stenosis who have:

• Reduced ejection fraction
• Prior myocardial infarction
• Arrhythmias
• Angina pectoris 1, 2, 1

A 2017 SEAS substudy of 1,873 patients with asymptomatic mild-to-moderate AS found beta-blocker use was associated with 50% lower all-cause mortality (HR 0.5,95% CI 0.3-0.7), 60% lower cardiovascular death (HR 0.4), and 80% lower sudden cardiac death (HR 0.2) 6. This challenges the traditional concern about negative inotropic effects.

Calcium Channel Blockers

Calcium channel blockers can be used safely in severe AS, contrary to historical concerns. A 2024 Japanese registry study (CURRENT AS-2) of 2,460 patients found:

• CCBs were the most commonly prescribed antihypertensive (71.7% of patients)
• No difference in 3-year all-cause death or heart failure hospitalization compared to non-CCB therapy (38.3% vs 38.7%, HR 0.94) 7
• Syncope was rare regardless of CCB use (1.1% vs 1.0%)

However, a 2020 review suggested CCBs may be associated with lower survival in observational studies, making them a second-line choice behind RAS blockers 8.

Diuretics

Use diuretics sparingly in patients with small LV chamber dimensions, as reduced preload may decrease cardiac output across the stenotic valve 1, 2, 9. They may have disadvantages in patients with LV hypertrophy and smaller LV cavity dimensions 8.

Critical Implementation Points

Starting and Titration Strategy

1. Start at low doses to avoid precipitous blood pressure drops
2. Gradually titrate upward with frequent clinical monitoring 1, 9
3. Target blood pressure: 130-139 mmHg systolic and 70-90 mmHg diastolic based on observational evidence 10, 8
4. Avoid aggressive lowering below these targets

Cardiology Consultation

In patients with moderate or severe aortic stenosis, consultation or co-management with a cardiologist is preferred for hypertension management 1, 2.

Common Pitfalls to Avoid

1. Withholding all antihypertensives due to fear of hypotension: The old dogma that AS represents "fixed obstruction" is incorrect. Multiple studies confirm antihypertensives are safe and beneficial 1, 9

2. Aggressive blood pressure lowering: Evidence suggests BP targets of 130-139/70-90 mmHg are optimal; lower targets should be avoided 8

3. Avoiding vasodilators entirely: Even nitroprusside has been shown to improve hemodynamics in severe AS by reducing total afterload 1, 2

4. Ignoring hypertension: The combination of hypertension and AS ("2 resistors in series") increases complications, cardiovascular morbidity, and mortality by 56-100% 9

Evidence Quality Note

There is no evidence that antihypertensive medications produce an inordinate degree of hypotension in patients with aortic stenosis 1, 2. Studies using nitroprusside in hypertensive patients with severe AS showed improvements in stroke volume and LV end-diastolic pressure 1, 2. The concern about "fixed obstruction" is not supported by contemporary evidence.